Skip to main content
Journal cover image

In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer.

Publication ,  Journal Article
Felker, ER; Lee-Felker, SA; Feller, J; Margolis, DJ; Lu, DS; Princenthal, R; May, S; Cohen, M; Huang, J; Yoshida, J; Greenwood, B; Kim, HJ; Raman, SS
Published in: Abdom Radiol (NY)
May 2016

PURPOSE: To determine the safety and efficacy of in-bore magnetic resonance-guided prostate biopsy (MRGB) for detection of clinically significant disease (CSD) in untreated men with known or suspected prostate cancer (PCa). METHODS: 512 patients underwent multiparametric magnetic resonance imaging (Mp-MRI) followed by MRGB at one of three centers in this IRB-approved, HIPAA-compliant, retrospective study. Exclusion criteria were prior prostate cancer therapy and incomplete Mp-MRI (n = 51). Patients (n = 461) were analyzed in two subcohorts: no prior PCa (NP) (n = 381) and active surveillance (AS) (n = 80). Detection rates of PCa and CSD (Gleason Score ≥3 + 4) were calculated and compared among subcohorts and by Mp-MRI assessment grade. Logistic regression was performed to identify predictors for detection of PCa and CSD. RESULTS: Mean patient age was 66 years, median prostate-specific antigen (PSA) was 7.5 ng/mL, and median prostate volume was 54 cc. A mean of 1.7 targets was sampled per gland. Significant adverse events (urosepsis and hematuria with obstruction) occurred in 1% (5/461). Overall PCa detection rates were 51% per patient (233/461) and 37% per lesion (282/757). 65% (151/233) of men with detected PCa had CSD. Per-patient PCa detection rates in the NP and AS subcohorts were 47% (178/381) and 69% (55/80), respectively, significantly higher in the AS group (p < 0.001). CSD was detected in 10% (47/451), 43% (96/225) and 84% (68/81) of lesions with Mp-MRI assessment grades of 3, 4, and 5, respectively. Older age, higher PSA, and lower prostate volume predicted MRGB detection of CSD (OR 1.07 and p = 0.003, OR 1.1 and p = 0.014, and OR 0.98 and p = 0.032, respectively). CONCLUSIONS: In-bore MRGB is safe and high yield for detection of CSD.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Abdom Radiol (NY)

DOI

EISSN

2366-0058

Publication Date

May 2016

Volume

41

Issue

5

Start / End Page

954 / 962

Location

United States

Related Subject Headings

  • Tumor Burden
  • Retrospective Studies
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Neoplasm Grading
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging, Interventional
  • Image-Guided Biopsy
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Felker, E. R., Lee-Felker, S. A., Feller, J., Margolis, D. J., Lu, D. S., Princenthal, R., … Raman, S. S. (2016). In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer. Abdom Radiol (NY), 41(5), 954–962. https://doi.org/10.1007/s00261-016-0750-7
Felker, Ely R., Stephanie A. Lee-Felker, John Feller, Daniel J. Margolis, David S. Lu, Robert Princenthal, Stuart May, et al. “In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer.Abdom Radiol (NY) 41, no. 5 (May 2016): 954–62. https://doi.org/10.1007/s00261-016-0750-7.
Felker ER, Lee-Felker SA, Feller J, Margolis DJ, Lu DS, Princenthal R, et al. In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer. Abdom Radiol (NY). 2016 May;41(5):954–62.
Felker, Ely R., et al. “In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer.Abdom Radiol (NY), vol. 41, no. 5, May 2016, pp. 954–62. Pubmed, doi:10.1007/s00261-016-0750-7.
Felker ER, Lee-Felker SA, Feller J, Margolis DJ, Lu DS, Princenthal R, May S, Cohen M, Huang J, Yoshida J, Greenwood B, Kim HJ, Raman SS. In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer. Abdom Radiol (NY). 2016 May;41(5):954–962.
Journal cover image

Published In

Abdom Radiol (NY)

DOI

EISSN

2366-0058

Publication Date

May 2016

Volume

41

Issue

5

Start / End Page

954 / 962

Location

United States

Related Subject Headings

  • Tumor Burden
  • Retrospective Studies
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Neoplasm Grading
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging, Interventional
  • Image-Guided Biopsy
  • Humans